CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) Fundamental Analysis & Valuation

NASDAQ:CYCCP • US23254L2079

Current stock price

5.05 USD
-0.23 (-4.36%)
Last:

This CYCCP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. CYCCP Profitability Analysis

1.1 Basic Checks

  • In the past year CYCCP has reported negative net income.
  • CYCCP had a negative operating cash flow in the past year.
  • CYCCP had negative earnings in each of the past 5 years.
  • In the past 5 years CYCCP always reported negative operating cash flow.
CYCCP Yearly Net Income VS EBIT VS OCF VS FCFCYCCP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • CYCCP has a worse Return On Assets (-146.06%) than 84.10% of its industry peers.
  • CYCCP has a Return On Equity of -177.03%. This is in the lower half of the industry: CYCCP underperforms 64.69% of its industry peers.
Industry RankSector Rank
ROA -146.06%
ROE -177.03%
ROIC N/A
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CYCCP Yearly ROA, ROE, ROICCYCCP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CYCCP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYCCP Yearly Profit, Operating, Gross MarginsCYCCP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. CYCCP Health Analysis

2.1 Basic Checks

  • CYCCP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CYCCP has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, CYCCP has more shares outstanding
  • There is no outstanding debt for CYCCP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CYCCP Yearly Shares OutstandingCYCCP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10K 20K 30K
CYCCP Yearly Total Debt VS Total AssetsCYCCP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • Based on the Altman-Z score of -138.50, we must say that CYCCP is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of CYCCP (-138.50) is worse than 97.04% of its industry peers.
  • CYCCP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -138.5
ROIC/WACCN/A
WACC9.66%
CYCCP Yearly LT Debt VS Equity VS FCFCYCCP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M 30M

2.3 Liquidity

  • CYCCP has a Current Ratio of 5.77. This indicates that CYCCP is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of CYCCP (5.77) is better than 61.74% of its industry peers.
  • A Quick Ratio of 5.77 indicates that CYCCP has no problem at all paying its short term obligations.
  • CYCCP's Quick ratio of 5.77 is fine compared to the rest of the industry. CYCCP outperforms 61.92% of its industry peers.
Industry RankSector Rank
Current Ratio 5.77
Quick Ratio 5.77
CYCCP Yearly Current Assets VS Current LiabilitesCYCCP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CYCCP Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 96.85% over the past year.
  • CYCCP shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -87.50%.
EPS 1Y (TTM)96.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.43%
Revenue 1Y (TTM)-87.5%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • The Earnings Per Share is expected to grow by 36.35% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 385.15% on average over the next years. This is a very strong growth
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5Y36.35%
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5Y385.15%

3.3 Evolution

CYCCP Yearly Revenue VS EstimatesCYCCP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2018 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M
CYCCP Yearly EPS VS EstimatesCYCCP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -5K -10K -15K -20K -25K

More info and screens

Find the best growth stocksShow best growing peers

1

4. CYCCP Valuation Analysis

4.1 Price/Earnings Ratio

  • CYCCP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CYCCP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYCCP Price Earnings VS Forward Price EarningsCYCCP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYCCP Per share dataCYCCP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80 -100

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CYCCP's earnings are expected to grow with 57.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.4%
EPS Next 3Y57.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CYCCP Dividend Analysis

5.1 Amount

  • No dividends for CYCCP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CYCCP Fundamentals: All Metrics, Ratios and Statistics

CYCLACEL PHARMACEUTICALS - CYCC 6 PERP

NASDAQ:CYCCP (9/11/2025, 8:00:01 PM)

5.05

-0.23 (-4.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12
Earnings (Next)11-10
Inst Owners6.61%
Inst Owner Change-61.5%
Ins Owners61.46%
Ins Owner ChangeN/A
Market Cap11.31M
Revenue(TTM)10.00K
Net Income(TTM)-6.43M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.03
Dividend Growth(5Y)-37.21%
DPN/A
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)-50.98%
Min Revenue beat(4)-100%
Max Revenue beat(4)96.08%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1131.2
P/FCF N/A
P/OCF N/A
P/B 3.12
P/tB 3.12
EV/EBITDA N/A
EPS(TTM)-122.02
EYN/A
EPS(NY)-1.14
Fwd EYN/A
FCF(TTM)-3.9
FCFYN/A
OCF(TTM)-3.9
OCFYN/A
SpS0
BVpS1.62
TBVpS1.62
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -146.06%
ROE -177.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.77
Quick Ratio 5.77
Altman-Z -138.5
F-Score3
WACC9.66%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.43%
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5Y36.35%
Revenue 1Y (TTM)-87.5%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5Y385.15%
EBIT growth 1Y48.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y57.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.04%
OCF growth 3YN/A
OCF growth 5YN/A

CYCLACEL PHARMACEUTICALS - CYCC 6 PERP / CYCCP Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) stock?

ChartMill assigns a fundamental rating of 3 / 10 to CYCCP.


What is the valuation status of CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) stock?

ChartMill assigns a valuation rating of 1 / 10 to CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP). This can be considered as Overvalued.


Can you provide the profitability details for CYCLACEL PHARMACEUTICALS - CYCC 6 PERP?

CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for CYCCP stock?

The Earnings per Share (EPS) of CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) is expected to grow by 39.49% in the next year.